Biopharmaceutical company with a focus on thalassemia after a setback in its sickle cell program.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Agios Pharmaceuticals, Inc. in the last 30 days yet.
The 1 sources with the most insights about Agios Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Considered 'pretty undervalued' with strong fundamentals, an approved drug, and a large cash position. However, the host sold his position to lock in profits after a quick rally from $22 to $25.
The speaker views the stock's 50% drop due to bad sickle cell data as a buying opportunity, believing the market has overreacted and the company is undervalued based on its cash and existing drugs.
Considered 'pretty undervalued' with strong fundamentals, an approved drug, and a large cash position. However, the host sold his position to lock in profits after a quick rally from $22 to $25.
The speaker views the stock's 50% drop due to bad sickle cell data as a buying opportunity, believing the market has overreacted and the company is undervalued based on its cash and existing drugs.
Other assets that creators frequently mention in the same content as Agios Pharmaceuticals, Inc..
The most active sources covering Agios Pharmaceuticals, Inc. (AGIO) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Agios Pharmaceuticals, Inc. (AGIO) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Agios Pharmaceuticals, Inc. (AGIO) most frequently also discuss QBTS, BTC, OLMA, PLTR, NVDA. See the "Discussed alongside" section above for full asset pages.